Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of olezarsen in severe hypertriglyceridemia
NL-OMON60820Phase 3Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jan 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olezarsen in hypertriglyceridemia, sponsored by Ionis Pharmaceuticals. Primary endpoints: Proportion of patients with specified laboratory safety changes from baseline, Proportion of participants who experience adverse events and 1 more. Started Jan 2024; status: active, not recruiting.
02
Drugs
olezarsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NL-OMON60820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60820.